casual obsever wrote:
rekrunner wrote:
Before that, I said I would ask two questions: 1) 4.7% of what? and 2) how did the controls perform?
As I said, I am at your service. Be patient please, I had other things to do yesterday.
Here you go:
The authors wrote:
The 650 kcal trial was chosen as it was expected to last ~40 min and would thus require high aerobic energy turnover. ... The primary outcome measures were mean power and time to completion. ... Once the subject reached 650 kcal, the trial was terminated.
...
The post hoc analysis revealed that following a low-volume transfusion, time trial mean power increased (P < 0.05) by 4.7 ± 1.6 %, while the mean power in the PLA trial was unaffected (0.3 ± 4.5 %). Time to completion became 4.4 ± 1.5 % faster after transfusion (P < 0.05) but was constant (-0.3 ± 4.5 %) in PLA.
PLA = placebo group
So, the doped group delivered 4.7% more power and was 4.4% faster, while there was no placebo effect.
4.4% faster: 0.044 x 40 min = 1.76 min = 1 min 46 s faster
Some other tidbits taken from the tables in the article:
After the smaller transfusion, Hb increased from 14.1 to 14.6 g/dL, and ret-% decreased from 1.62 to 1.45%. Adding the larger RBC amount led to a further jump to Hb = 15.5 g/dL and decline to 1.21 ret-% (Table 1). The Hb change was not (just) a concentration effect, because the Hb mass increased also, from 833 g to 906 g (Table 2). That's a 9% increase in mass and a 10% increase in concentration.
All indeed well below the ABP thresholds. See Ashenden's 2011 paper (doi 10.1007/s00421-011-1867-6). See also this Kenyan study you enjoyed even less than I did.
Fun exercise: compare the changes here (from 14.1 to 15.5 g/dL, and 1.62% to 1.21%) with Paula's from 2003 (from 12 to 15.6 g/dL, and 0.59% to 0.47%, within a few days, not at altitude).
P.S. As for micro-doping/dosing I laughed about earlier: that came from the journalist, not the authors (or you) who never used "micro". Their point is "low volume", in contrast to the two bags normally used (see the fun exercise above).
For the motivation, as well as a brief summary of other studies, see the intro:
The authors wrote:
The effect of autologous blood transfusion (ABT) on exercise performance has been studied for more than a half century (1, 2). It is evident that >800 ml ABT of whole blood or a corresponding volume of red blood cells (RBCs) improves aerobic exercise performance (1, 3-7). However, when the ABT volume is smaller, the result is less clear. Only few studies are available, and the lowest transfusion volumes currently studied are 450-500 ml, corresponding to one bag of whole blood, which improves 3 km treadmill time trial performance (8) and time to exhaustion at peak aerobic workload (9). However, others report unaffected time to exhaustion (10, 11). Furthermore, a ‘one-bag’ study (8) has reported increased whole-body peak oxygen uptake (VO2peak), but other studies (9, 12) reported no difference. One possible explanation for the unclear result from the available low-volume ABT studies may be lack of well-controlled designs, including blinded randomized crossover trials. Whether a low-volume ABT systematically improves exercise performance is highly relevant in an anti-doping context, since dishonest athletes are suspected to utilize low (≤150-200 ml) ABT volumes (13).
Finally, "dishonest athletes are suspected to utilize low (≤150-200 ml) ABT volumes" is exactly what I wrote here in October (200 ml is standard nowadays, except for too ambitious drug cheats).